Claims

1. A pharmaceutical combination comprising:
(a) a Hsp90 inhibitor compound that is 5-(2,4-Dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide or a pharmaceutically acceptable salt thereof; and
(b) an mTOR inhibitor that is everolimus.

2. Use of a first pharmaceutical component for the manufacture of a medicament for treating a proliferative disease in combination with a second pharmaceutical component, wherein the first pharmaceutical component is a Hsp90 inhibitor that is 5-(2,4-Dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide or a pharmaceutically acceptable salt thereof;
wherein the second pharmaceutical component is an mTOR inhibitor that is everolimus, and wherein the proliferative disease is a carcinoma.

3. The use according to claim 2, wherein said medicament and the mTOR inhibitor are to be administered together as a single pharmaceutical composition.

4. The use according to claim 2, wherein said medicament and the mTOR inhibitor are to be administered as separate compositions.

5. The use according to claim 2, wherein said medicament and the mTOR inhibitor are to be administered sequentially.

6. A combination comprising:
(a) a first pharmaceutical composition comprising an Hsp90 inhibitor that is 5-(2,4-Dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-yl-methyl-phenyl)-isoxazole-3-carboxylic acid ethylamide or a pharmaceutically acceptable salt thereof; and
(b) an mTOR inhibitor that is everolimus, in a second pharmaceutically acceptable carrier.